Benzinga | Aug 27, 2020 08:01AM EDT

CymaBay Therapeutics Presents Positive Final Results From 52-Week Phase 2 Study In Primary Biliary Cholangitis At The Digital International Liver Congress 2020

* Sustained anti-cholestatic and hepatoprotective effects observed in patients with and without cirrhosis

* Self-reported pruritus improved at one year for patients in highest categories of baseline itch

* Selected for inclusion in the "Best of ILC" presentation Results mirror recently reported ENHANCE Phase 3 data confirming anti-cholestatic and anti-pruritic effects of seladelpar